sacituzumab govitecan
gilead sciences
['sacituzumab', 'bcsm', 'breast']
compared with chemotherapy, sacituzumab govitecan led to better progression-free survival outcomes in patients with hormone receptor positive, her2-negative breast cancer. #bcsm #asco22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.